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INTRODUCTION
Evidence indicates that an intimate relationship exists between host lipid metabolism and intracellular pathogens (Baek et al., 2011; Bard et al., 2005; Coppens, 2013; Griffin et al., 2012) . Perturbations in host lipid homeostasis are observed in viral and microbial infections (Cui et al., 2014; Greseth and Traktman, 2014; Herker and Ott, 2011) . While it remains mechanistically unclear as to how each invading pathogen subverts host lipid metabolism, it has been proposed that co-opting host metabolism is a general strategy employed by pathogens to meet the anabolic requirements of pathogen lifecycle and to facilitate evasion from host defense (Cui et al., 2014; Greseth and Traktman, 2014; Heaton et al., 2010; Herker and Ott, 2011; Kapadia and Chisari, 2005; Ouellet et al., 2011) . Consistent with this concept, genetic or pharmacologic inhibition of host lipid metabolism has been shown to attenuate pathogenesis of both viral and microbial infections in a number of model systems (Gilbert et al., 2005; Herker and Ott, 2011; Liu et al., 2008; Munger et al., 2008; Parihar et al., 2014; Petersen et al., 2014; Rzouq et al., 2014) .
Cumulatively, these studies suggest that co-opting host lipid metabolism facilitates microbial or viral pathogenesis, and leads to the hypothesis that host defense pathways should attempt to overwrite the metabolic changes induced by invading pathogens. In support of this concept, recent studies have demonstrated that components of host responses to pathogens (e.g., Toll-like receptor [TLR] 3/4 and type I interferon [IFN] signaling) specifically rewire the lipid metabolic program by downregulating de novo cholesterol biosynthesis at the genetic level (Blanc et al., 2011 (Blanc et al., , 2013 Liu et al., 2013; Reboldi et al., 2014) . Thus, it has been suggested that the influence of type I IFN signaling on cholesterol homeostasis would serve to limit the availability of lipid metabolites for intracellular organisms. In contrast, other studies have shown that these same inflammatory signals (e.g., TLR3/4 and type I IFNs) increase lipid uptake from environmental sources, resulting in the accumulation of neutral lipids and ultimately facilitating foam cell formation (Dushkin and Kovshik, 2013; Funk et al., 1993; Huang et al., 2014; Keyel et al., 2012) . Thus, it remains unclear if the purpose of type I IFN-mediated metabolic reprogramming is to specifically limit the availability of lipid metabolites (e.g., cholesterol) for pathogens as has been proposed, or if there are alternative reasons for the selective reprogramming of flux through the cholesterol biosynthetic pathway. Herein, we examine this question and delineate a lipid metabolic-inflammatory circuit that links the induction of type I IFNmediated inflammation with perturbations in the pool size of synthesized cholesterol. Using stable isotope enrichment analysis, we demonstrate that type I IFN signaling shifts the balance of lipid metabolism away from de novo synthesis to favor lipid import without limiting total long-chain fatty acid and cholesterol content in macrophages. Strikingly, we find that genetically enforcing this shift in lipid homeostasis in macrophages alone is sufficient to protect mice from viral challenge, demonstrating the importance of reprogramming the ''set point'' between synthesis and import in host defense. Unexpectedly, we find that limiting flux through the cholesterol biosynthetic pathway spontaneously induces a type I IFN response that primes cells for heightened anti-viral immunity in both an autocrine and paracrine manner. Mechanistic studies indicate that the STING (TMEM173) signaling axis is required to link the induction of a type I IFN response with alterations in flux through the mevalonate pathway. Replenishing free cholesterol was able to normalize type I IFN levels by limiting STING signaling in cells lacking enzymes of the mevalonate pathway, establishing the importance of cholesterol homeostasis in type-I-mediated inflammation.
RESULTS

Reprogramming the Balance of Lipid Synthesis and Import in Macrophages
To better understand how type I IFN signaling modulates the balance of lipid synthesis and import, we employed gas chromatography-mass spectrometry (GC-MS) paired with 13 C-stable isotope enrichment studies to measure total and synthesized cholesterol and long-chain fatty acid levels in mouse bonemarrow-derived macrophages (BMDMs) stimulated with IFNb, Poly:IC (TLR3 agonist) or infected with murine gammaherpesvirus-68 (MHV-68). Isotopic spectral analysis (ISA) was applied to the mass isotopomer distributions to derive the contribution of de novo synthesis to the total cholesterol and long-chain fatty acid pools over the labeling period. Treatment of BMDMs with either IFNb or Poly:IC significantly decreased the synthesis of saturated long-chain fatty acids (16:0, 18:0), unsaturated long-chain fatty acids (18:1), and cholesterol (Figures 1A and S1A) . However, total fatty acid (16:0, 18:0, 18:1, and 18:2) and cholesterol content increased on a per cell basis (Figures 1B and S1B) , suggesting that these cells increase lipid import. Consistent with our MS studies, we observed a significant increase in the uptake of dil-acetylated LDL in response to Poly:IC or IFNb stimulation in BMDMs ( Figure S1C ). Importantly, infection of BMDMs with MHV-68 drove a similar shift in the balance of lipid synthesis and import in an interferon a/b receptor (IFNAR)-dependent manner, indicating that type I IFNs mediate lipid metabolic reprogramming ( Figures 1A, 1B , S1A, and S1B). We also considered the possibility that the availability of environmental lipids would influence IFN-mediated reprogramming. To address this, we cultured BMDMs with increasing percentages of serum (5%, 10%, and 20%) before stimulation with IFNb. ISA modeling indicated that type I IFN treatment consistently decreased de novo synthesis of cholesterol and increased import to nearly the same extent in all serum conditions ( Figure S1D ).
Next, we examined the expression pattern of genes involved in cholesterol and fatty acid synthesis and import in MHV-infected BMDMs. We observed that infection decreased expression of genes encoding enzymes of the de novo cholesterol and fatty acid biosynthetic pathways ( Figure 1C ), similar to previous studies on cholesterol synthesis using cytomegalovirus (Blanc et al., 2013) . MHV infection also significantly increased expression of genes involved in lipid import, including Macrophage Scavenger Receptor (Msr1) and the fatty acid translocase Cd36 ( Figures 1C and S1E) . Stimulation of BMDMs with IFNb or Poly:IC for 24 hr revealed a similar reprogramming at the gene and protein expression level ( Figures S1F and S1G ). Importantly, blocking IFNAR signaling abrogated reprogramming of lipid metabolism driven by either MHV-68 infection or type I IFN stimulation ( Figures 1C and S1G ). Thus, we conclude that type I IFN signals reprogram the balance of lipid synthesis and import within a macrophage but do not appear to specifically limit cholesterol and long-chain fatty acid availability.
Loss of SREBP Activity Shifts the Balance of Lipid Synthesis and Import
The results of our isotope labeling studies led us to ask if this shift in the balance of lipid homeostasis driven by type I IFN is an important component of host defense. To directly address this would require a genetic model where the ''set point'' controlling the balance of lipid synthesis and scavenging was shifted independent of TLR and IFNAR signaling. To accomplish this, we generated mice with macrophage-specific deletion of SREBP cleavage-activating protein (gene: Scap; protein: SCAP) using the LysM-Cre model. SCAP is an endoplasmic reticulum (ER) sterol-sensing protein required to chaperone (D) the sterol regulatory element binding proteins (SREBP1 and SREBP2) (Horton et al., 2002) . Upon genetic deletion of Scap, SREBP1 and 2 transcriptional activities are significantly attenuated, resulting in markedly reduced expression of cholesterol and fatty acid biosynthesis genes (see Figure S2A for schematic) .
As expected, gene expression analysis of BMDMs confirmed that genetic deletion of Scap markedly decreases expression of the genes encoding enzymes of the de novo cholesterol and fatty acid biosynthetic programs ( Figure 1D ). However, loss-of-Scap does not appear to influence the in vitro differentiation of BMDMs ( Figure S2B ) nor impact the frequency of macrophages or other immune cell populations in lymph node, spleen, and bone marrow ( Figure S2C ). Next, we performed 13 C-isotope enrichment and ISA to determine if loss-of-Scap altered lipid biosynthetic capacity. We observed that the contribution of synthesis to total lipid pools in Scap À/À BMDMs was decreased compared to controls (Figures 1E and S2D) . However, total cholesterol and fatty acid pool sizes were similar between IFNb-treated control and Scap À/À BMDMs ( Figure 1F ), demonstrating that loss-ofScap does not significantly decrease the total amounts of these lipids in BMDMs. Taken together, these data demonstrate that Scap-deficiency phenocopies the shift in lipid homeostasis observed in response to IFNb stimulation.
Loss of Scap Protects from Viral Inflection
Next, we sought to determine whether genetically enforcing this metabolic shift in macrophages influenced host defense. To begin investigating this, control and Scap intranasally with MHV-68. Similar to our in vitro results, we found that the loss-of-Scap in macrophages alone was sufficient to reduce viral load in lungs by over 90% ( Figure 2C ). Taken together, our data indicate that genetic deletion of Scap can be protective in viral infections and support the concept that lipid metabolic reprogramming can be a protective component of host response to viral infections.
Loss of Scap Primes a Type I IFN Response
MHV replicates in a number of cell types, including macrophages and type 1 and type 2 pneumocytes (Hughes et al., 2010) , leading us to hypothesize that viral resistance conferred by loss-of-Scap in macrophages may be transferable to neighboring cells. To directly test this, conditioned media (CM) from naive control or Scap À/À macrophages was collected and transferred to wildtype (WT; C57BL/6) BMDM cultures before challenge with MHV-68 (see Figure S3A for schematic). Remarkably, transfer of Scap À/À CM to WT BMDM cultures was able to reduce MHV-68 viral burden by $50% ( Figure 2D ). These results indicate that the viral resistance phenotype observed in Scap-deficient macrophages occurs, at least in part, through the production of secreted factors that then prime cells for anti-viral immunity. Type I IFNs are secreted proteins that are important for antiviral immunity, leading us to ask if genetic deletion of Scap influenced type I IFN responses. Gene expression studies on unstimulated BMDMs revealed that loss-of-Scap results in the spontaneous induction of a type I IFN-inflammatory response characterized by heightened Ifnb1 and interferon-stimulated genes (ISGs, e.g., Mx1, Mx2, Irf7, Ccl2, and Cxcl10) ( Figure 2E ). Heightened ISG expression was also observed in alveolar macrophages from LysM-Cre IFNs. In support of this, transfer of culture supernatants from unstimulated Scap À/À BMDMs to quiescent WT macrophages was able to induce an ISG signature ( Figure 2H ). We also observed the upregulation of a type I IFN signature in human THP1 macrophages in response to either stable or transient silencing of SCAP ( Figures S3C and S3D) . Importantly, addition of IFNAR blocking antibody abrogated antiviral capacity of CM from Scap À/À BMDMs ( Figure 2I ), supporting the concept that the anti-viral effect of Scap deficiency was, in large part, mediated through production of type I IFNs. Next, we assessed the ability of Scap-deficient macrophages to respond to TLR3/4 and IFNAR signaling. We observed that both human and mouse Scap-deficient macrophages have significantly heightened induction of Ifnb1 and ISGs in response to both lipopolysaccharide (LPS) and Poly:IC, as well as type I IFN treatment ( Figure 2J , left, and Figures S3E-S3G ). Interestingly, not all inflammatory responses were upregulated in Scap-deficient macrophages. We found that induction of Il1b, (J) qPCR analysis of Ifnb1 and Il1b expression in control or Scap À/À BMDMs unstimulated or stimulated with LPS (50 ng/ml) or Poly:IC (1 mg/ml) for 1 hr on day 8 of differentiation. All experiments are reported as means ± SD from three independent experiments, unless noted otherwise. *p < 0.05, **p < 0.01, and ***p < 0.005 (two-tailed unpaired Student's t test). See also Figure S3 . a canonical pro-inflammatory factor downstream of TLR4 activation, was significantly attenuated in response to LPS ( Figure 2J , right). IFNAR blockade was able to partially restore upregulation of Il1b expression in TLR4-stimulated Scap-deficient macrophages ( Figure S3H ), indicating that type IFN signaling contributes, in part, to repression of Il1b in LPS-stimulated cells. Taken together, these data indicate that reprogramming of lipid metabolism can prime macrophages for heightened IFN responses to PAMPs or cytokine signals; however, this type of metabolic reprogramming also entrains specific inflammatory responses at the expense of other inflammatory programs.
Induction of a Type I IFN Signature Segregates with Loss of SREBP2
Scap is required for activation of all isoforms of the SREBP transcription factors. In mammals, there are two SREBP genes that express three SREBP proteins. SREBP1a and SREBP1c are produced via alternative transcriptional start sites on SREBF1, whereas the SREBF2 gene encodes SREBP2 (Horton et al., 2002) . In general, SREBP1 activates transcription of genes involved in fatty acid synthesis, while SREBP2 is responsible for transcriptionally activating genes required for cholesterol synthesis (schematic Figure S2A ). To determine if the ISG signature observed in Scap-deficient macrophages was dependent on loss of the SREBP1 or SREBP2 transcriptional axis, we generated THP1 macrophages stably expressing shRNA targeting either SREBF1 or SREBF2 (designated herein as shSREBP1 or shSREBP2, respectively) and performed RNA-sequencing studies on unstimulated macrophages. As expected, knockdown of SREBP1 attenuated expression of genes involved in fatty acid synthesis, whereas loss of SREBP2 decreased expression of cholesterol biosynthesis genes ( Figures S4A and S4B ). Bioinformatic analysis of RNA-seq data indicated that heightened expression of ISGs, and enrichment of pathways involved in host defense to viral infection, segregated entirely with the loss of SREBP2 expression ( Figures 3A and S4C ). Quantitative PCR (qPCR) analysis confirmed that silencing of SREBP2 in primary human PBMC-derived macrophages or THP1 cells resulted in heightened basal expression of IFNB1 and an ISG signature ( Figures 3B, S4D , and S4E). In line with this pro-inflammatory phenotype, SREBP2-deficient macrophages were significantly resistant to Influenza A and HIV-1 challenge ( Figures 3C  and S4F ). In contrast, a type I IFN signature was not observed in shSREBP1 macrophages ( Figures 3A, 3B , and S4E), indicating that the spontaneous induction of type I interferon-mediated inflammation occurs specifically in response to genetically perturbing the SCAP/SREBP2 pathway. Nearly every cell in the body has the ability to produce type I IFNs; thus, we sought to determine if genetic deletion of SREBP2 in non-immune cells would also result in the spontaneous induction of type I IFN and resistance to viral challenge. To that end, we examined the basal expression levels of ISGs from Srebp2 null mouse embryonic fibroblasts (designated SREBP2 À/À MEFs). Similar to our studies in macrophages, we observed that SREBP2 À/À MEFs constitutively expressed heightened levels of Ifnb1 and ISGs ( Figure 3D ), and IFNAR blockade significantly reduced ISG expression to that of control MEFs ( Figure 3E ). Correspondingly, SREBP2 À/À MEFs were significantly resistant to MHV-68 challenge ( Figure 3F ) and produced heightened ISGs in response to MHV infection ( Figure 3G ). Importantly, pretreatment with IFNAR-neutralizing antibodies was sufficient to abrogate the heightened anti-viral immunity observed in SREBP2 À/À MEFs ( Figure 3H ), indicating that the anti-viral immunity seen in SREBP2-deficient cells is largely dependent on IFNAR signaling.
Limiting Flux through the Mevalonate Pathway Engages a Type I IFN Response Mevalonate kinase deficiency (MKD) is an autosomal recessive disease caused by significantly decreased enzymatic activity of mevalonate kinase (MVK) (Esposito et al., 2014; Santos et al., 2014) . Individuals with moderate residual enzymatic activity ($20% of WT) are characterized by recurrent episodic fevers, persistent inflammatory responses, and hyper IgD production (termed hyperimmunoglobulinemia D with periodic fever syndrome or HIDS). SREBP2 has a well-defined role in transcriptionally regulating the enzymes involved in the mevalonate pathway (Horton et al., 2002) , leading us to ask if MKD results in the spontaneous generation of type I IFN-mediated inflammation. Examination of primary fibroblasts from an individual with MKD revealed heightened basal ISG expression when compared to population controls ( Figure 4A ). Genetic silencing of MVK or HMGCR (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis, in macrophages also resulted in the upregulation of IFNB1 and ISGs ( Figures 4B, S5A , and S5B). In contrast, silencing of stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in flux through the long-chain fatty acid biosynthetic pathway , did not induce ISGs ( Figures S5A and S5C ). Importantly, we also find that MKD fibroblasts are primed for exaggerated type I IFN-mediated inflammatory responses. Activation of MKD fibroblasts with Poly:IC resulted in a significantly heightened ISG signature (Figure 4C) . Taken together, these data indicate that decreasing flux through the mevalonate pathway results in the upregulation of a type I IFN response and provide a potential mechanistic explanation for the inflammatory symptoms and immune dysregulation observed in individuals with MKD. Intermediary metabolites of cholesterol biosynthesis have been shown to activate the liver X receptors (LXRa and b), nuclear receptors with a clear role in repressing lipid-driven metabolic inflammation (Glass and Witztum, 2001; Shibata and Glass, 2009; Spann et al., 2012; Yang et al., 2006) . Consistent with this, we found that LXR target genes ABCA1 and IDOL were significantly decreased in both SREBP2-and SCAP-deficient macrophages ( Figure 4D ). Thus, we considered the possibility that the upregulation of IFNB1 and downstream ISGs resulted from decreased LXR signaling. However, treatment of SREBP2-deficient macrophages with LXR ligand GW3965, which restored LXR function ( Figure S5D ), failed to reduce expression of ISGs ( Figure 4E ). These findings indicate that LXRs do not repress type I IFN-mediated inflammation and are in agreement with previous work (Castrillo et al., 2003) . (H) qPCR analysis of MHV-68 ORF57 expression in WT or SREBP2 À/À MEFs infected with MHV-68 (MOI = 1.0) for 24 hr ± 24 hr pretreatment with 5 mg/ml IFNAR blocking antibody. All experiments are reported as means ± SD from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.005 (two-tailed unpaired Student's t test). See also Figure S4 . inflammation, leading us to ask if replenishing cholesterol could attenuate this inflammatory program. To this end, control and SREBP2-deficient macrophage cultures were treated with methyl-beta-cyclodextrin conjugated cholesterol (MbCDcholesterol) to supplement free cholesterol levels in loss-of-function cells. Supplementing SREBP2-deficient macrophages with MbCD-cholesterol significantly reduced the expression of ISGs ( Figure 4F ). Thus, we conclude that restoring cholesterol homeostasis alone is sufficient to abrogate the induction of a type I IFN signature in cells that have the mevalonate pathway perturbed. Consistent with this, replenishing cholesterol in Scap À/À BMDMs abrogated the anti-viral phenotype ( Figure 4G ). In combination, these data suggest that acutely decreasing synthesized cholesterol appears to provide a novel ''danger'' signal that activates a type I IFN-mediated anti-viral response.
IRF3 Links Perturbations in Cholesterol Homeostasis to
Ifnb1 Transcription Finally, we sought to define the molecular mechanism linking perturbations in cholesterol biosynthesis with the spontaneous induction of type I interferon-mediated inflammation. We had observed that IFNAR blockade reduced ISG expression ( Figures  2G and 3E ) but was not able to decrease Ifnb1 gene expression in both SCAP-and SREBP2-deficient cells ( Figure 5A , left, and S6A). However, addition of MbCD-cholesterol was able to reduce the expression level of Ifnb1 ( Figure 5A , right, and S6B), supporting a model where induction of inflammation in SREBP2-or SCAP-deficient cells is dependent on transcriptional upregulation of Ifnb1. Interferon Regulatory Factor 3 and 7 (IRF3 and IRF7) are transcription factors with well-defined roles in the transcriptional regulation of Ifnb1 (Fitzgerald et al., 2003; Honda et al., 2005) . We observed that SREBP2-deficeint cells had significantly elevated expression of IRF7 ( Figures 2E, 3A, and 5B), leading us to ask if IRF7 was important in mediating inflammation. To address this, we transiently silenced Irf3 or Irf7 in SREBP2 À/À MEFs ( Figure 5B ). We observed that silencing of Irf7 was able to partially reduce ISG expression ( Figure 5C ) but had no influence on Ifnb1 expression ( Figure 5C , left). In contrast, silencing of Irf3 completely abrogated Ifnb1 expression and correspondingly attenuated ISG expression ( Figure 5C ). Taken together, these data indicate that IRF3 is required to drive the spontaneous upregulation of Ifnb1 and ISGs observed in SREBP2-deficient cells and that IRF7 serves to amplify the ISG program.
STING Links Changes in Cholesterol Synthesis with IFNb Production
Stimulator of Interferon Genes (STING; TMEM173) and Mitochondrial Antiviral-Signaling (MAVS) pathways are known to facilitate IRF3 nuclear translocation and Ifnb1 transcription in response to cytosolic double-stranded DNA or RNA, respectively (Ishikawa and Barber, 2008; Seth et al., 2005; Sun et al., 2013; Tanaka and Chen, 2012) . To determine if these pathways were contributing to IRF3 activation and Ifnb1 expression, we silenced MAVS or STING in SREBP2-deficient cells. Silencing of MAVS had no effect on heightened Ifnb1 and ISG expression in SREBP2-deficient MEFs ( Figures 5D and S6C ).
In contrast, silencing of STING completely abrogated heightened Ifnb1 and ISG expression in MEFs and macrophages ( Figures 5D, 5E , and S6C-S6G). STING ligands (cyclic di-nucleotides) can be generated by the enzymatic activity of cyclic GMP-AMP (cGAMP) synthase (cGAS; Mb21d1). Gene expression studies revealed that SREBP2-deficeint cells have basally heightened expression of cGAS ( Figure S6C ), which is partially dependent on STING, IRF3, and IFNAR signaling ( Figures S6C,  S6H , and S6I). Transiently silencing cGAS reduced the expression of Ifnb1 and ISGs in SREBP2-deficient cells to that of controls, indicating that heightened STING activity observed in SREBP2 À/À cells is dependent on generation of endogenous STING ligands ( Figure 5F ). STING is an ER-resident protein that promotes phosphorylation of TANK-binding kinase 1 (TBK1) and IRF3 in response to cyclic di-nucleotides (Tanaka and Chen, 2012) . Western blot analysis demonstrated increased basal phospho-TBK1 in SREBP2 À/À MEFs ( Figure 6A ). Silencing of Tbk1 alone was sufficient to reduce expression of Ifnb1 and ISGs ( Figure 6B ) in SREBP2 À/À cells. Likewise, silencing of STING or cGAS attenuated heightened pTBK1 ( Figure 6C ). Taken together, these data confirm a requirement for the cGAS/STING/TBK1/IRF3 signaling axis in linking changes in cholesterol metabolism with induction of Ifnb1.
We posited that addition of exogenous cholesterol should reduce signaling activity through the STING/TBK1 pathway. Replenishing cholesterol to Scap À/À BMDMs significantly reduced phospho-TBK1 levels ( Figure 6D ), whereas IFNAR blockade had no effect on pTBK1 ( Figures 6A and 6D ). These data suggest that cholesterol levels directly influence the ability of STING to transduce signals to TBK1. To address this, control and Scap (MOI = 0.5) for 24 hr. All experiments are reported as means ± SD from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.005 (two-tailed unpaired Student's t test). See also Figure S5 . 
(legend continued on next page)
BMDMs were treated with a low dose of exogenous STING ligand (herein denoted as ''cGMP''). We observed that cGMP treatment significantly increased pTBK1 levels in Scap
BMDMs compared to that of controls ( Figure 6E) . Importantly, addition of cholesterol to these cells markedly diminished cGMP induced Ifnb1 expression ( Figure 6F ). Taken together, these data support a model where perturbations in cholesterol biosynthetic flux intrinsically influence responsiveness of STING/TBK1 axis to cyclic di-nucleotides and provide a molecular mechanism linking cholesterol homeostasis with type I IFNmediated inflammation.
DISCUSSION
In this study, we identify a metabolic-inflammatory circuit that is an important component of host defense. We initially show that decreasing de novo cholesterol and fatty acid biosynthesis is a physiologic response to viral infection via the IFNAR signaling pathway, in agreement with other recently published gene expression studies (Blanc et al., 2011; Reboldi et al., 2014) . One potential explanation for this is that decreasing lipid synthesis may serve to limit the amount of lipids available to invading pathogens. However, our studies also indicate that these same pro-inflammatory signals maintain or increase the cellular pool size of cholesterol and long-chain fatty acids, suggesting that type I IFN-mediated reprogramming of lipid metabolism is to alter the balance between lipid synthesis and scavenging, rather than to decrease lipid pool sizes. These data also suggest that limiting intracellular lipid metabolite availability (e.g., cholesterol) for pathogen utilization is a less likely explanation for why IFN signals downregulate de novo lipid synthesis. Rather, our data indicate that selectively decreasing flux through the cholesterol biosynthetic pathway engages a type I IFN response and primes cells for heightened anti-viral immunity. In this way, IFN signaling decreases cholesterol biosynthesis, and in a reciprocal manner, acutely decreasing cholesterol biosynthesis drives type I IFN responses. Therefore, we conclude that the mevalonate pathway and IFN-signaling pathway are part of a metabolic-inflammatory circuit that ensures any changes in the activity of one pathway are sensed by the other pathway. One striking implication of our data is that synthesized lipids convey unique information about cellular status despite being chemically indistinguishable from their imported counterparts. A simple explanation for this observation is that de novo synthesized lipids are initially partitioned into the ER bilayer before being distributed to subcellular pools or the plasma membrane (Horton et al., 2002) . In contrast, lipid import occurs at the plasma membrane and must transit through a number of cellular processing/transport pathways before reaching the ER or other organelles (Das et al., 2014; Wang et al., 2010) . As such, subcellular concentration of a specific lipid species would convey information regarding cellular metabolic homeostasis. Indeed, this is the operating principle underlying the tight regulation of the SREBP pathway, where ER sterol content is monitored by the SCAP and INSIG proteins (Radhakrishnan et al., 2008; Sun et al., 2007) . STING protein is in also embedded in the ER membrane (Ishikawa and Barber, 2008) ; thus, we propose a model where the STING signaling axis is activated in response to decreasing the ER bilayer cholesterol pool size. Moreover, given that all nucleated cells have the ability to synthesize cholesterol and that STING is expressed in a wide variety of cell types, we predict that this metabolic inflammatory circuit is likely to exist in a broad array of tissues.
As to how perturbations in the pool size of synthesized cholesterol directly engage the STING pathway remains unclear at this time. We considered the possibility that perturbing flux through the cholesterol biosynthetic pathway could significantly increase intracellular levels of STING ligands (Sun et al., 2013) . However, cGAMP levels in both control and SREBP2-deficient cells remained below our limits of detection by LC-MS ($240 fmole; data not shown [West et al., 2015; White et al., 2014] ). Thus, we believe it unlikely that changes in cholesterol homeostasis are significantly altering the levels of endogenous STING ligands in cells. Rather, we propose a model where decreasing cholesterol levels in the ER membrane facilitate STING/TBK1 interactions. In this system, STING from SREBP2-deficient cells would respond more efficiently to the same amount of cGAS-produced ligand, explaining the requirement for cGAS for enhanced IFNb production in SREBP2-deficient cells. Of course, it remains possible that cholesterol is also regulating the function of other components of this signaling axis (e.g., cGAS or TBK1), and it will be important in future studies to mechanistically address these questions.
Finally, our observation that cholesterol pool size can be monitored by host defense machinery raises the intriguing possibility that other classes of lipids are also monitored through yet-to-bedefined sensor-signaling pathways. Indeed, our data indicate that IFNAR signaling can also limit flux through the de novo fatty acid biosynthetic program, but the immunological consequences of this observation still remain unclear. Further experiments will be required to elucidate the signaling pathways involved in shaping the lipid ''codes'' enforced by innate immune receptors and to fully appreciate the role of lipid metabolic reprogramming during the innate immune response. In conclusion, the studies presented herein provide mechanistic insights as to how perturbations in cholesterol homeostasis engage inflammatory pathways and advance our understanding of the crosstalk between lipid metabolism and host defense. (E) Western blot analysis of pTBK1 and TBK1 total in control or Scap À/À BMDMs ± 5 mg/ml c-di-GMP (cGMP) for 45 min.
(F) qPCR analysis of Ifnb1 expression in control or Scap À/À BMDMs cultured ± 0.25 mg/ml MbCD-cholesterol for 48 hr and then stimulated with 5 mg/ml cGMP for Human Cell Lines THP1 cells cultured in RPMI media with 10% FBS (Omega Scientific) with penicillin/streptomycin (GIBCO). THP1 cells were differentiated with phorbol 12-myristate 13-acetate (PMA) at 50 ng/ml (EMD Millipore) for 48-96 hr, depending on the experiment. For viral infection studies, THP1 cells were differentiated for 72 hr prior to infection.
Primary Human Cells
Human monocyte-derived macrophage: peripheral blood mononuclear cells (PBMCs) were isolated from leukopacks using standard ficoll procedures. Monocytes were separated from PBMCs via plastic adherence. Monocytes were differentiated into macrophage with 10 ng/ml human M-CSF (Biolegend) in RPMI (GIBCO) media with 10% FBS for 7 days prior to experimental use. Human primary fibroblasts from MVK-deficient (Cat. GM12014) or population controls (Cat. ND38530) were obtained from Coriell Institute for Medical Research and cultured under recommended conditions.
Mouse Cells
Bone marrow was differentiated into macrophages in DMEM containing 20% FBS (Omega), 5% M-CSF conditioned media, 1% pen/strep (GIBCO), 1% glutamine (Invitrogen), and 0.5% sodium pyruvate (Invitrogen) for 7-9 days prior to experimental use. WT and SREBP2 À/À MEFs were obtained from Dr.
Karen Reue (UCLA). Mouse embryonic fibroblasts (MEFs) were cultured in DMEM plus 10% FBS with 1% Pen/Strep unless noted otherwise.
Viruses HIV1 was produced by transfecting 293T cells with pHIV 89.6 using lipofectamin 2000 (Life Technology) according to the manufacturer's protocol. HIV1 89.6 was harvested 2 days after transfection and purified with 0.22 mm filter and quantified by p24 ELISA. Influenza A/WSN/33 (H1N1) was produced by transfecting 293T cells with the 8-plasmid reverse genetics system (Neumann et al., 1999) . WT MHV-68 was purchased from ATCC. For all in vitro infection experiments, cells were infected with virus for 3 hr and then changed into fresh media.
RNA-Seq
RNA was purified using QIAGEN RNeasy Kit and submitted to the UCLA Clinical Microarray Core for RNA-seq analysis (see Supplemental Experimental Procedures for details of methods and analysis). Data are available at http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73942.
U 13 C-Glucose Labeling of Cells and Isotope Enrichment Analysis
Day 8 differentiated BMDMs were labeled with U 13 C-glucose, and ISA was performed as previously described . Please see Supplemental Experimental Procedures for detailed methods.
ACCESSION NUMBERS
The accession number for the data reported in this paper is GEO: GSE73942. 
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